254 related articles for article (PubMed ID: 8983283)
21. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I
Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130
[TBL] [Abstract][Full Text] [Related]
22. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
23. A prospective, randomized, double-blinded, placebo-controlled trial of empirical teicoplanin in febrile neutropenia with persistent fever after imipenem monotherapy.
Erjavec Z; de Vries-Hospers HG; Laseur M; Halie RM; Daenen S
J Antimicrob Chemother; 2000 Jun; 45(6):843-9. PubMed ID: 10837439
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
[TBL] [Abstract][Full Text] [Related]
25. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of three types of empirical antibiotherapy in patients with febrile neutropenia: imipenem-cilastatin versus ceftazidime-vancomycin versus ticarcillin-amikacin-vancomycin].
Bosseray A; Nicolini F; Brion JP; Michallet M; Hollard D; Stahl JP; Micoud M
Pathol Biol (Paris); 1992 Oct; 40(8):797-804. PubMed ID: 1484739
[TBL] [Abstract][Full Text] [Related]
27. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
[TBL] [Abstract][Full Text] [Related]
28. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
[TBL] [Abstract][Full Text] [Related]
29. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer).
Biron P; Fuhrmann C; Cure H; Viens P; Lefebvre D; Thyss A; Viot M; Soler-Michel P; Rollin C; Grès JJ
J Antimicrob Chemother; 1998 Oct; 42(4):511-8. PubMed ID: 9818751
[TBL] [Abstract][Full Text] [Related]
30. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.
Raad II; Whimbey EE; Rolston KV; Abi-Said D; Hachem RY; Pandya RG; Ghaddar HM; Karl CL; Bodey GP
Cancer; 1996 Apr; 77(7):1386-94. PubMed ID: 8608520
[TBL] [Abstract][Full Text] [Related]
31. Clinical experience with three combination regimens for the treatment of high-risk febrile neutropenia.
Serefhanoglu K; Ersoy Y; Serefhanoglu S; Aydogdu I; Kuku I; Kaya E
Ann Acad Med Singap; 2006 Jan; 35(1):11-6. PubMed ID: 16470268
[TBL] [Abstract][Full Text] [Related]
32. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
[TBL] [Abstract][Full Text] [Related]
33. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Marie JP; Vekhoff A; Pico JL; Guy H; Andremont A; Richet H
J Antimicrob Chemother; 1998 Jun; 41 Suppl D():57-64. PubMed ID: 9688452
[TBL] [Abstract][Full Text] [Related]
34. Comparison of meropenem with ceftazidime as monotherapy of cancer patients with chemotherapy induced febrile neutropenia.
Malik I; Shaharyar
J Pak Med Assoc; 2002 Jan; 52(1):15-8. PubMed ID: 11963577
[TBL] [Abstract][Full Text] [Related]
35. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
[TBL] [Abstract][Full Text] [Related]
36. Monotherapy for empirical management of febrile neutropenic patients.
Rubin M; Pizzo PA
NCI Monogr; 1990; (9):111-6. PubMed ID: 2160613
[TBL] [Abstract][Full Text] [Related]
37. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever.
Engervall P; Günther G; Ljungman P; Lönnqvist B; Hast R; Stiernstedt G; Kalin M; Ringertz S; Bjökholm M
Scand J Infect Dis; 1996; 28(3):297-303. PubMed ID: 8863366
[TBL] [Abstract][Full Text] [Related]
38. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
Fanci R; Paci C; Martinez RL; Fabbri A; Pecile P; Leoni F; Longo G
J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
[TBL] [Abstract][Full Text] [Related]
39. Empiric monotherapy in neutropenia: a realistic goal?
Del Favero A; Bucaneve G; Menichetti F
Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
[TBL] [Abstract][Full Text] [Related]
40. [Febrile neutropenia: empiric antibiotic therapy from 1975 to 1997].
Klastersky J
Rev Med Brux; 1997 Oct; 18(5):323-7. PubMed ID: 9441328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
